Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease
- PMID: 23365250
- PMCID: PMC6571077
- DOI: 10.1523/JNEUROSCI.4437-12.2013
Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease
Abstract
Diffusion imaging is a promising marker of microstructural damage in neurodegenerative disorders, but interpretation of its relationship with underlying neuropathology can be complex. Here, we examined both volumetric and brain microstructure abnormalities in 13 amnestic patients with mild cognitive impairment (MCI), who progressed to probable Alzheimer's disease (AD) no earlier than 2 years after baseline scanning, in order to focus on early, and hence more sensitive, imaging markers. We compared them to 22 stable amnestic MCI patients with similar cognitive performance and episodic memory impairment but who did not show progression of symptoms for at least 3 years. Significant group differences were mainly found in the volume and microstructure of the left hippocampus, while white matter group differences were also found in the body of the fornix, left fimbria, and superior longitudinal fasciculus (SLF). Diffusion index abnormalities in the SLF were the sign of a subtle microstructural injury not detected by standard atrophy measures in the corresponding gray matter regions. The microstructural measure obtained in the left hippocampus using diffusion imaging showed the most substantial differences between the two groups and was the best single predictor of future progression to AD. An optimal prediction model (91% accuracy, 85% sensitivity, 96% specificity) was obtained by combining MRI measures and CSF protein biomarkers. These results highlight the benefit of using the information of brain microstructural damage, in addition to traditional gray matter volume, to detect early, subtle abnormalities in MCI prior to clinical progression to probable AD and, in combination with CSF markers, to accurately predict such progression.
Figures






Similar articles
-
Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.Cochrane Database Syst Rev. 2020 Mar 2;3(3):CD009628. doi: 10.1002/14651858.CD009628.pub2. Cochrane Database Syst Rev. 2020. PMID: 32119112 Free PMC article.
-
The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11. J Intern Med. 2014. PMID: 24237038
-
Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.J Alzheimers Dis. 2019;69(1):49-58. doi: 10.3233/JAD-181016. J Alzheimers Dis. 2019. PMID: 30958351
-
Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014. Neuroimage Clin. 2013. PMID: 24371799 Free PMC article.
-
Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.Alzheimers Res Ther. 2017 Oct 10;9(1):84. doi: 10.1186/s13195-017-0301-7. Alzheimers Res Ther. 2017. PMID: 29017593 Free PMC article.
Cited by
-
Alterations of White Matter Connectivity in Adults with Essential Hypertension.Int J Gen Med. 2024 Jan 31;17:335-346. doi: 10.2147/IJGM.S444384. eCollection 2024. Int J Gen Med. 2024. PMID: 38314198 Free PMC article. Clinical Trial.
-
Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.Cochrane Database Syst Rev. 2020 Mar 2;3(3):CD009628. doi: 10.1002/14651858.CD009628.pub2. Cochrane Database Syst Rev. 2020. PMID: 32119112 Free PMC article.
-
TRPM2 Channel Aggravates CNS Inflammation and Cognitive Impairment via Activation of Microglia in Chronic Cerebral Hypoperfusion.J Neurosci. 2018 Apr 4;38(14):3520-3533. doi: 10.1523/JNEUROSCI.2451-17.2018. Epub 2018 Mar 9. J Neurosci. 2018. PMID: 29507145 Free PMC article.
-
Differential Role for Hippocampal Subfields in Alzheimer's Disease Progression Revealed with Deep Learning.Cereb Cortex. 2022 Jan 22;32(3):467-478. doi: 10.1093/cercor/bhab223. Cereb Cortex. 2022. PMID: 34322704 Free PMC article.
-
The emerging agenda of stratified medicine in neurology.Nat Rev Neurol. 2014 Jan;10(1):15-26. doi: 10.1038/nrneurol.2013.245. Epub 2013 Dec 10. Nat Rev Neurol. 2014. PMID: 24323053 Review.
References
-
- Agosta F, Pievani M, Sala S, Geroldi C, Galluzzi S, Frisoni GB, Filippi M. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology. 2011;258:853–863. - PubMed
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
-
- Amunts K, Kedo O, Kindler M, Pieperhoff P, Mohlberg H, Shah NJ, Habel U, Schneider F, Zilles K. Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol (Berl) 2005;210:343–352. - PubMed
-
- Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709–7717. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical